AstraZeneca shares rise
AstraZeneca’s shares rise as it addresses China investigation
In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company confirmed that its Chinese business is under investigation for alleged unpaid import taxes on certain cancer drugs, including Imfinzi (durvalumab) and Imjudo (tremelimumab).
AstraZeneca shares rise as China probe update reassures
AstraZeneca shares rose on Thursday after the drugmaker said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes for two cancer drugs, reassuring analysts and investors that the business impact would be minor.
The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.
Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...
A Liberal Democrat peer has accused the government of favouring the south-east of England over Merseyside after AstraZeneca ...
Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...
AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...
FTSE 100 heavyweight AstraZeneca helped propel the blue-chip index to a record high today. Here's what investors were ...
GlobalData on MSN10h
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trialResearchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with ...
AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback